First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.

about

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.

Item

http://www.wikidata.org/entity/Q52598812

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.

@en

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.

@nl

type

Item

label

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.

@en

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.

@nl

prefLabel

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.

@en

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.

@nl

P1476

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis

@en

P2093

Cécile Camberlin

http://www.w3.org/2001/XMLSchema#string

Joan Vlayen

http://www.w3.org/2001/XMLSchema#string

Stephan Devriese

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence based medicine: what it is and what it isn't

Patient preferences in advanced or recurrent ovarian cancer.

Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.

A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada.

The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.

P304

e0195134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0195134

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mattias Neyt

P577

2018-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29630612

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

bevacizumab

P932

5891000

http://www.w3.org/2001/XMLSchema#string